HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.
Fecal microbiome
HIV controllers
HIV‐1 rebound
Immune activation
TLR7
Vesatolimod
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
revised:
19
04
2024
received:
27
02
2024
accepted:
30
04
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
10
5
2024
Statut:
aheadofprint
Résumé
HIV infection is associated with gut dysbiosis, and microbiome variability may affect HIV control when antiretroviral therapy (ART) is stopped. The TLR7 agonist, vesatolimod, was previously associated with a modest delay in viral rebound following analytical treatment interruption in HIV controllers (HCs). Using a retrospective analysis of fecal samples from HCs treated with vesatolimod or placebo (NCT03060447), people with chronic HIV (CH; NCT02858401) or without HIV (PWOH), we examined fecal microbiome profile in HCs before/after treatment, and in CH and PWOH. Microbiome diversity and abundance were compared between groups to investigate the association between specific phyla/species, immune biomarkers, and viral outcomes during treatment interruption. Although there were no significant differences in gut microbiome diversity between people with and without HIV, HCs, and CH shared common features that distinguished them from PWOH. there was a trend toward greater microbiome diversity among HCs. Treatment with vesatolimod reduced dysbiosis in HCs. Firmicutes positively correlated with T-cell activation, while Bacteroidetes and Euryarchaeota inversely correlated with TLR7-mediated immune activation. Specific types of fecal microbiome abundance (e.g. Alistipes putredinis) positively correlated with HIV rebound. In conclusion, variability in the composition of the fecal microbiome is associated with markers of immune activation following vesatolimod treatment and ART interruption.
Identifiants
pubmed: 38727191
doi: 10.1002/eji.202350809
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2350809Subventions
Organisme : Gilead Sciences
Informations de copyright
© 2024 Wiley‐VCH GmbH.
Références
Zheng, D., Liwinski, T. and Elinav, E., Interaction between microbiota and immunity in health and disease. Cell Res. 2020. 30: 492–506.
Onabajo, O. O. and Mattapallil, J. J., Gut microbiome homeostasis and the CD4 T‐ follicular helper cell IgA axis in human immunodeficiency virus infection. Front. Immunol. 2021. 12: 657679.
Assimakopoulos, S. F., Dimitropoulou, D., Marangos, M. and Gogos, C. A., Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies. Infection 2014. 42: 951–959.
Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., Kazzaz, Z. et al., Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 2006. 12: 1365–1371.
Busman‐Sahay, K., Starke, C. E., Nekorchuk, M. D. and Estes, J. D., Eliminating HIV reservoirs for a cure: the issue is in the tissue. Curr. Opin. HIV AIDS 2021. 16: 200–208.
Borgognone, A., Noguera‐Julian, M., Oriol, B., Noel‐Romas, L., Ruiz‐Riol, M., Guillen, Y., Parera, M. et al., Gut microbiome signatures linked to HIV‐1 reservoir size and viremia control. Microbiome 2022. 10: 59.
Gonzalo‐Gil, E., Ikediobi, U. and Sutton, R. E., Mechanisms of virologic control and clinical characteristics of HIV+ elite/viremic controllers. Yale J. Biol. Med. 2017. 90: 245–259.
Martinsen, J. T., Gunst, J. D., Hojen, J. F., Tolstrup, M. and Sogaard, O. S., The use of toll‐like receptor agonists in HIV‐1 cure strategies. Front. Immunol. 2020. 11: 1112.
Tsai, A., Irrinki, A., Kaur, J., Cihlar, T., Kukolj, G., Sloan, D. D. and Murry, J. P., Toll‐like receptor 7 agonist GS‐9620 induces HIV expression and HIV‐specific immunity in cells from HIV‐infected individuals on suppressive antiretroviral therapy. J. Virol. 2017. 91: e02166–02116.
SenGupta, D., Brinson, C., DeJesus, E., Mills, A., Shalit, P., Guo, S., Cai, Y. et al., The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. Sci. Transl. Med. 2021. 13: eabg3071.
Lopatin, U., Wolfgang, G., Tumas, D., Frey, C. R., Ohmstede, C., Hesselgesser, J., Kearney, B. et al., Safety, pharmacokinetics and pharmacodynamics of GS‐9620, an oral toll‐like receptor 7 agonist. Antivir. Ther. 2013. 18: 409–418.
Lawitz, E., Gruener, D., Marbury, T., Hill, J., Webster, L., Hassman, D., Nguyen, A. H. et al., Safety, pharmacokinetics and pharmacodynamics of the oral toll‐like receptor 7 agonist GS‐9620 in treatment‐naive patients with chronic hepatitis C. Antivir. Ther. 2015. 20: 699–708.
Riddler, S. A., Para, M., Benson, C. A., Mills, A., Ramgopal, M., DeJesus, E., Brinson, C. et al., Vesatolimod, a toll‐like receptor 7 agonist, induces immune activation in virally suppressed adults living with human immunodeficiency virus‐1. Clin. Infect. Dis. 2021. 72: e815–e824.
Pan, H., Guo, R., Ju, Y., Wang, Q., Zhu, J., Xie, Y., Zheng, Y. et al., A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. Microbiome 2019. 7: 107.
Dillon, S. M., Frank, D. N. and Wilson, C. C., The gut microbiome and HIV‐1 pathogenesis: a two‐way street. AIDS 2016. 30: 2737–2751.
Vesterbacka, J., Rivera, J., Noyan, K., Parera, M., Neogi, U., Calle, M., Paredes, R. et al., Richer gut microbiota with distinct metabolic profile in HIV infected elite controllers. Sci. Rep. 2017. 7: 6269.
Nowak, P., Troseid, M., Avershina, E., Barqasho, B., Neogi, U., Holm, K., Hov, J. R. et al., Gut microbiota diversity predicts immune status in HIV‐1 infection. AIDS 2015. 29: 2409–2418.
Scher, J. U., Sczesnak, A., Longman, R. S., Segata, N., Ubeda, C., Bielski, C., Rostron, T. et al., Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013. 2: e01202.
Iljazovic, A., Roy, U., Galvez, E. J. C., Lesker, T. R., Zhao, B., Gronow, A., Amend, L. et al., Perturbation of the gut microbiome by Prevotella spp. enhances host susceptibility to mucosal inflammation. Mucosal. Immunol. 2021. 14: 113–124.
Lu, W., Feng, Y., Jing, F., Han, Y., Lyu, N., Liu, F., Li, J. et al., Association between gut microbiota and CD4 recovery in HIV‐1 infected patients. Front. Microbiol. 2018. 9: 1451.
Kaur, U. S., Shet, A., Rajnala, N., Gopalan, B. P., Moar, P., D. H., Singh, B. P. et al., High abundance of genus Prevotella in the gut of perinatally HIV‐infected children is associated with IP‐10 levels despite therapy. Sci. Rep. 2018. 8: 17679.
Ezeji, J. C., Sarikonda, D. K., Hopperton, A., Erkkila, H. L., Cohen, D. E., Martinez, S. P., Cominelli, F. et al., Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health. Gut. Microbes 2021. 13: 1922241.
Geuking, M. B. and Burkhard, R., Microbial modulation of intestinal T helper cell responses and implications for disease and therapy. Mucosal. Immunol. 2020. 13: 855–866.
Khan, M. T., Dwibedi, C., Sundh, D., Pradhan, M., Kraft, J. D., Caesar, R., Tremaroli, V. et al., Synergy and oxygen adaptation for development of next‐generation probiotics. Nature 2023. 620: 381–385.
Coutinho, C., Coutinho‐Silva, R., Zinkevich, V., Pearce, C. B., Ojcius, D. M. and Beech, I., Sulphate‐reducing bacteria from ulcerative colitis patients induce apoptosis of gastrointestinal epithelial cells. Microb. Pathog. 2017. 112: 126–134.
Pasolli, E., Schiffer, L., Manghi, P., Renson, A., Obenchain, V., Truong, D. T., Beghini, F. et al., Accessible, curated metagenomic data through ExperimentHub. Nat. Methods 2017. 14: 1023–1024.
Yeoh, Y. K., Sun, Y., Ip, L. Y. T., Wang, L., Chan, F. K. L., Miao, Y. and Ng, S. C., Prevotella species in the human gut is primarily comprised of Prevotella copri, Prevotella stercorea and related lineages. Sci. Rep. 2022. 12: 9055. PMID:35641510.
Chen, L., Shen, Y., Wang, C., Ding, L., Zhao, F., Wang, M., Fu, J. et al., Megasphaera elsdenii lactate degradation pattern shifts in rumen acidosis models. Front. Microbiol. 2019. 10: 162.
Fulcher, J. A., Li, F., Tobin, N. H., Zabih, S., Elliott, J., Clark, J. L., D'Aquila, R. et al., Gut dysbiosis and inflammatory blood markers precede HIV with limited changes after early seroconversion. EBioMedicine 2022. 84: 104286.
Guo, X., Wang, Z., Qu, M., Guo, Y., Yu, M., Hong, W., Zhang, C. et al., Abnormal blood microbiota profiles are associated with inflammation and immune restoration in HIV/AIDS individuals. mSystems 2023. 8: e0046723.
Yoshida, N., Emoto, T., Yamashita, T., Watanabe, H., Hayashi, T., Tabata, T., Hoshi, N. et al., Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation 2018. 138: 2486–2498.
Ling, Z., Jin, C., Xie, T., Cheng, Y., Li, L. and Wu, N., Alterations in the fecal microbiota of patients with HIV‐1 infection: an observational study in a Chinese population. Sci. Rep. 2016. 6: 30673.
Dillon, S. M., Kibbie, J., Lee, E. J., Guo, K., Santiago, M. L., Austin, G. L., Gianella, S. et al., Low abundance of colonic butyrate‐producing bacteria in HIV infection is associated with microbial translocation and immune activation. AIDS 2017. 31: 511–521.
Vacca, M., Celano, G., Calabrese, F. M., Portincasa, P., Gobbetti, M. and De, A. M., The controversial role of human gut lachnospiraceae. Microorganisms 2020. 8: 573.
Bosco, N. and Noti, M., The aging gut microbiome and its impact on host immunity. Genes Immun. 2021. 22: 289–303.
Souyris, M., Cenac, C., Azar, P., Daviaud, D., Canivet, A., Grunenwald, S., Pienkowski, C. et al., TLR7 escapes X chromosome inactivation in immune cells. Sci. Immunol. 2018. 3: eaap8855.
Souyris, M., Mejia, J. E., Chaumeil, J. and Guery, J. C., Female predisposition to TLR7‐driven autoimmunity: gene dosage and the escape from X chromosome inactivation. Semin. Immunopathol. 2019. 41: 153–164.
Theze, J., Chakrabarti, L. A., Vingert, B., Porichis, F. and Kaufmann, D. E., HIV controllers: a multifactorial phenotype of spontaneous viral suppression. Clin. Immunol. 2011. 141: 15–30.
Chao, A. and Bunge, J., Estimating the number of species in a stochastic abundance model. Biometrics 2002. 58: 531–539.
Bruner, K. M., Wang, Z., Simonetti, F. R., Bender, A. M., Kwon, K. J., Sengupta, S., Fray, E. J. et al., A quantitative approach for measuring the reservoir of latent HIV‐1 proviruses. Nature 2019. 566: 120–125.